Recently, it was shown that the presence of the FBP1 protein increases the sensitivity of pancreatic cancer cells to the bromodomain and extraterminal domain (BET) inhibitor JQ1, highlighting FBP1’s possible role in individualized cancer therapy (Wang et al. 2018). Here, FBP1 is linked to pancreatic neoplasm.